Mitokinin
A veteran entrepreneur who has cofounded three companies across the technology and life sciences industries, Mr. de Roulet brings a background in finance and startup management to the Mitokinin team. Prior to founding Mitokinin, Mr. de Roulet co-founded and served as co-CEO at Knowify, a leading SaaS business management platform for contractors. He began his career in the financial services industry, serving as an equity analyst at LaBranche & Company before joining Bishop & Carroll Capital Partners, a long-short equity hedge fund.
Mr. de Roulet graduated from Columbia University with a BA in Economics.
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.